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Parkinson’s disease (PD) is characterized by deficits in goal-directed behavior as well 
as mood and motivational symptoms, including apathy, depression, and anxiety. The 
present study investigated novelty processing in PD, using event-related potentials 
(ERPs) to characterize electrophysiological reflections of visual novelty processing. Since 
apathy has been associated with decreased novelty processing (P3 potentials) in highly 
apathetic PD patients, we were particularly interested to see if this relationship exists in a 
sample of PD patients with heterogeneous levels of apathy. Non-demented patients with 
PD receiving dopaminergic treatment (n = 14) and healthy control participants (n = 12) 
completed a three-stimulus oddball task while EEG was recorded. Relative to controls, 
the PD patients exhibited reductions in centrofrontally distributed P3 potentials when 
viewing novel distracters during this task. Distracter-related P3 amplitudes evoked by 
novel distracters were strongly associated with apathy symptoms, even after controlling 
for the effects of depression, anxiety, and executive function. Executive dysfunction was 
also predictive of novelty-related P3 processing, yet this relationship was independent 
from that of apathy. These findings suggest that the brain’s electrophysiological response 
to novelty is closely related to both motivational and cognitive symptoms in PD, even 
for patients whose apathy symptoms are not excessive. These results have significant 
implications for our understanding of non-motor symptoms in this clinical population.
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inTrODUcTiOn
Along with its hallmark motor symptoms, Parkinson’s disease (PD) has long been recognized for 
its associated cognitive and emotional deficits. Approximately 25–30% of PD patients develop 
dementia (1), yet even PD patients without dementia typically experience cognitive deficiencies. 
It has long been shown that non-demented PD patients struggle to process novel input that requires 
flexibility and planning (2), initiate goal-directed behavior (3), and monitor current behavior (4). 
Recent electrophysiological studies have found that certain measures of spontaneous EEG may 
serve as important biomarkers for cognitive decline in PD (5–7).
In addition to motor and cognitive dysfunction, more than 50% display symptoms of apathy 
(8, 9) and ~40–50% of PD patients manifest symptoms of depression (10–12). Mood dysregula-
tion in PD appears to consist of dissociable factors of apathy, dysphoria, anhedonia, and somatic 
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complaints (13). Mood symptoms are among the key factors 
leading to decreased quality of life in this population (14, 15), yet 
there is little neurophysiological evidence to link these symptoms 
to cognitive deficits in PD.
apathy in PD
Apathy is viewed as a lack of motivation that includes cognitive, 
affective, and behavioral components (16). In PD, apathy can 
manifest as decreased initiative to act or carry out activities 
(behavioral apathy), decreased reactivity and physiological 
blunting (affective apathy), and decreased interest in goals and 
planning (cognitive apathy). Early reports found that 12% of 
PD patients presented with apathy without depression as their 
primary symptom (9), while this number has been estimated to 
be as high as 29% (17). Apathy has been associated with execu-
tive dysfunction in PD (8, 18). Highly apathetic PD patients tend 
to exhibit poorer executive functions and heightened levels of 
depression and anxiety compared to patients with low levels of 
apathy (19); however, these findings appear to be influenced by 
the presence of dopaminergic treatment. While some patients 
appear to improve their apathy symptoms by taking dopaminer-
gic medications, those with DOPA-resistant apathy demonstrate 
structural changes in the basal ganglia, including atrophy of the 
nucleus accumbens and head of the caudate (20).
novelty Processing in PD
Efficient processing of novelty is critical to goal-directed behavior 
because it drives the flexible allocation of attention that facilitates 
adaptation to changing environmental demands. Novel events 
can serve as either potential sources of engagement or as irrelevant 
distracters that should be ignored. Event-related potential (ERP) 
methods can be used to track the process of attentional orient-
ing, which measures the cognitive resources directed toward 
deviant events that are unique or unexpected. When using ERPs 
to examine novelty processing, distracter-related P3 potentials 
(also known as P3a or novelty P3) have frequently been observed 
with a frontal or central scalp distribution (21, 22). In these para-
digms, P3 potentials are evoked most prominently by infrequent, 
task-irrelevant distracters. Accordingly, this distracter-related P3 
component has often been interpreted as reflecting an automatic, 
orienting reflex toward unexpected, novel events (23), which is 
believed to be a fundamental biological mechanism that influ-
ences exploratory behavior (24).
With regard to novelty processing, Tsuchiya et  al. (25) 
found that PD patients exhibited reduced P3 responses to novel 
distracters, and these P3 reductions correlated with decreased 
performance on a modified version of the Wisconsin Card 
Sorting Test (WCST). This finding suggests that novelty pro-
cessing deficits in PD may be related to executive functioning 
deficits that are often seen in this population (26). More recently, 
frontocentral P3 amplitude has been associated with disease 
duration and severity in PD (27). Additionally, PD patients with 
clinically elevated levels of apathy have demonstrated reduced 
electrophysiological reflections of novelty processing over 
frontal electrodes, relative to patients with low levels of apathy 
(19). Indeed, it appears that many neurological populations 
demonstrate a relationship between apathy and novelty ERPs, 
including Alzheimer’s disease (28), cortical stroke (29, 30), and 
subcortical stroke (31).
Overview of the current study
The purpose of the present study was to examine ERP correlates 
of novelty processing in PD and healthy controls in order to 
further examine how apathy symptoms are associated with dis-
rupted allocation of attention in PD patients. To do so, we used a 
visual three-stimulus oddball task and manipulated the distracter 
type. This approach enabled us to investigate effects of distracter 
novelty on ERP reflections of visual novelty. Unlike other investi-
gators (19), we wanted to test the hypothesis that apathy is related 
to reduced novelty processing in a heterogeneous sample of PD 
patients, including those with and without elevations in apathy. 
We predicted that increased apathy symptoms in medicated PD 
patients would be associated with reduced reflections novelty 
processing, regardless of the specific level of apathy reported. 
In line with previous research, associations between novelty 
processing and executive dysfunction were also expected.
MaTerials anD MeThODs
Participants
Fourteen non-demented PD patients and 12 age-matched con-
trols participated in the current study. All patients had a diagnosis 
of idiopathic PD by a movement disorders specialist according 
to the UK Brain Bank criteria. Exclusion criteria included a 
history of severe psychiatric illness (i.e., schizophrenia, current 
depression episode, etc.), neurologic disorders affecting the brain 
other than PD (e.g., traumatic brain injury, stroke, tumor), severe 
sensory deficits, and scores below 26 on the mini-mental state 
examination [MMSE; (32)]. Cognitive, emotional, and electro-
physiological testing sessions were performed while patients were 
on dopaminergic medications.
Table 1 depicts a summary of demographic, disease severity, 
neurocognitive, and mood information. Overall, participants 
were predominantly male and ranged in age from 35 to 77 years. 
The control group had a trend toward higher levels of education 
(p >  0.08), but did not differ on any other demographic vari-
able. Patients performed more poorly on measures of executive 
function and endorsed more symptoms of depression and anxiety 
than controls. Although the two groups were statistically matched 
on apathy scores, PD patients had a greater range (0–25) than 
controls (3–18). The majority of individuals scored below the 
clinical cut-off score for apathy (<14) in both the PD (79%) and 
control (92%) groups. In terms of disease characteristics, the PD 
patients were in the early-to-mid range of disease severity, based 
on Hoehn–Yahr (H–Y) staging (33) and motor scores from the 
United Parkinson Disease Rating Scale [UPDRS; (34)] obtained 
within 12  months of testing. Sixty-two percent of PD patients 
were in H–Y stage 2, 15% were in stage 2.5, 15% were in stage 
3, and 7% were in stage 4. Disease duration ranged from 5 to 
15 years.
event-related Potential stimuli and Task
Testing took place in an electrically shielded and sound-attenuated 
room. All PD patients were evaluated when on their normal 
TaBle 1 | Demographic and neuropsychological data for healthy controls 
and PD patients.
controls (n = 12) PD patients (n = 14)
Mean sD Mean sD p
Demographics
Age (years) 61.7 11.8 63.3 9.1 ns
Education (years) 16.0 3.0 13.7 3.4 ns
Female (%) 42 – 21 – ns
Right-handed (%) 92 – 100 – ns
emotional functioning
AS 7.7 4.1 9.7 8.3 ns
BDI-II 2.7 3.3 11.7 8.2 <0.01
STAI – trait 28.1 6.5 37.5 12.0 <0.05
STAI – state 28.5 6.5 37.9 10.8 <0.05
cognitive functioning
MMSE 28.7 1.3 29.2 1.1 ns
Dementia Rating Scale – – 136.4 6.9
Boston Naming Test 56.7 4.1 56.7 2.5 ns
COWA (FAS) 40.0 10.4 37.9 15.8 ns
Semantic fluency (animals) 21.9 4.6 19.3 7.0 ns
Digit span forward 
(WAIS-III)
7.1 1.3 7.1 1.0 ns
Digit span backward 
(WAIS-III)
5.3 1.5 5.7 1.5 ns
Trails A (s) 27.7 9.4 47.2 26.3 <0.05
Trails B (s) 68.0 28.0 122.8 57.7 <0.01
Stroop word reading 97.3 11.5 87.2 14.8 ns
Stroop color naming 71.9 15.1 65.9 13.6 ns
Stroop color-word naming 36.8 13.5 33.6 12.1 ns
WCST categories 
completed
5.7 1.1 3.7 1.8 <0.01
WCST total errors 18.8 16.7 40.9 17.1 <0.01
WCST perseverative 
responses
10.8 10.1 22.8 10.9 0.01
WCST set failure 0.3 0.7 1.4 0.9 <0.01
Disease characteristics
Duration of symptoms 
(years)
– – 10.1 2.9 –
UPDRS motor – On Meds – – 25.4 13.5 –
UPDRS motor – Off Meds – – 34.1 12.4 –
Levodopa equivalent dose – – 1179.7 670.9 –
Antidepressant 
medications (%)
– – 21 – –
BDI-II, Beck Depression Inventory, Second Edition; AS, Apathy Scale; STAI, State-Trait 
Anxiety Inventory; MMSE, mini-mental state examination; COWA, Controlled Auditory 
Word Association Test; WAIS-III, Wechsler Adult Intelligence Scale, Third Edition; 
WCST, Wisconsin Card Sorting Test; UPDRS, Unified Parkinson’s disease rating scale.
FigUre 1 | stimuli used in the two blocks of the oddball task. 
(a) All stimuli in the gray distracter block comprised an identical gray color. 
(B) Standards and targets in the color distracter block were identical to those 
presented in the gray distracter block, but the distracters consisted of unique 
colorful fractal designs. Adapted from Kaufman et al. (36).
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dosage of dopaminergic medications. Stimuli and procedures 
for the three-stimulus oddball task were adapted from Polich 
and Comerchero (35). Distracter novelty was manipulated by 
stimulus features contained within the large squares. Half of the 
distracters were gray, like the targets and standards, and were 
identical in appearance throughout the experiment. The other 
distracters contained colorful fractal designs that were unique 
and only occurred once over the course of the experiment. 
Mean (±SD) luminance intensity for the color distracter slides 
was 24.1 ± 9.3 cd/m2, which did not deviate substantially from 
that of gray distracters (23.1 cd/m2). Following a brief practice 
trial, a total of 600 stimuli were randomly presented in four 
blocks of 150. Each stimulus was presented for 75  ms, with 
a 2-s inter-stimulus interval. Color and gray distracters were 
presented in different (counterbalanced) trial blocks to allow 
the opportunity to examine the block-related effects of distracter 
type on behavioral and electrophysiological data. See Figure  1 
for a sample color distracter and an overview of the stimulus 
probabilities.
electrophysiological Data recording, 
reduction, and Measurement
Electroencephalogram data were recorded from the scalp using a 
64-channel system (Electrical Geodesics, Inc., Eugene, OR, USA) 
running Net Station software. Impedance of electrodes was main-
tained below 50 kΩ, as recommended by the manufacturer. EEG 
was initially referenced to the vertex and recorded continuously at 
250 Hz, with on-line band-pass filtering from 0.1 to 100 Hz. EEG 
data were then re-referenced to a right mastoid reference off-line 
and digitally low-pass filtered at 30 Hz. Following recording, EEG 
data were adjusted for movement, electromyographic muscle 
artifact, electro-ocular eye movement, and blink artifacts using 
spatial filtering methods implemented through Brain Electric 
Source Analysis [BESA; (37)]. See Figure S1 in Supplementary 
Material for topography of blink artifacts. All EEG data above 
150 μV was discarded, and the maximum allowable amplitude 
settings for each trial were individualized for each participant 
[as recommended by (38)]. The average (±SD) amplitude used 
for rejection was 111 μV (±14), and this threshold did not differ 
TaBle 2 | Behavioral data from the oddball task.
controls PD patients
Mean sD Mean sD
gray distracter
Reaction time to targets (ms) 473.2 70.9 478.0 103.6
Target response errors (%) 1.8 2.4 10.0 10.6
False alarm to distracters (%) 0.4 0.9 5.4 10.4
False alarm to standards (%) 0.2 0.3 4.7 9.3
color distracter
Reaction time to targets (ms) 460.6 74.7 491.1 73.5
Target response errors (%) 1.5 2.7 5.3 7.7
False alarm to distracters (%) 4.6 0.6 5.9 3.7
False alarm to standards (%) 0.4 0.5 2.3 4.5
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between PD patients and controls [t(24) = 1.1, p > 0.30]. Point-
to-point transitions were not allowed to exceed 75 μV. Of the 
64 electrodes used to collect data, a small number of electrodes 
were interpolated during analysis in order to reduce electrode 
noise. PD patients required greater electrode interpolation than 
controls [t(24) = 3.2, p < 0.01], which is likely due to additional 
movement artifact caused by Parkinsonian tremors during the 
EEG recording. Nevertheless, PD patients as a whole required 
minimal electrode interpolation (8% of electrodes, on average).
Individual-subject stimulus-locked averages were derived 
separately for standard, target, and distracter stimuli in each 
of the two distracter blocks. Epochs were extracted from a 
window of 200 ms prior- to 800 ms post-stimulus presentation 
and baseline-corrected (200 ms prior to stimulus onset) before 
subject averaging and analysis. Four midline electrodes corre-
sponding with FCz, Cz, CPz, Pz were chosen for measurement 
and analysis of P3 responses, as these electrodes demonstrated 
the maximal amplitude of this component. Four centrofrontal 
electrodes were chosen to examine anterior P3 difference 
waves. The time window used for scoring the P3 component 
was 300–650 ms.
Data analysis
Due to a positive skew in the accuracy data, we applied the arcsine 
transformation for all error rate data (36) and subjected them 
to a Group (PD, control) × Distracter (gray, color) × Stimulus 
(standard, target, distracter) repeated measures analysis of 
variance (ANOVA). For analyses of oddball task response time 
(RT), median RTs were employed for correct responses (39) and 
compared between distracter conditions via dependent sample 
t-tests.
Because of their broad scalp distribution, P3 mean ampli-
tudes and peak latencies were examined with Group (PD, 
control) × Distracter (gray, color) × Stimulus (standard, target, 
distracter) × Electrode Site (FCz, Cz, CPz, Pz) repeated measures 
ANOVAs. All other ERP components were subjected to Group 
(PD, control) ×  Distracter (gray, color) ×  Stimulus (standard, 
target, distracter) repeated measures ANOVAs performed on 
the electrode location(s) in which each ERP component showed 
maximal amplitude (40). ANOVAs employed planned contrasts 
to examine main effects and interactions, with effect sizes reported 
as partial eta-squared (η2). For ANOVAs examining effects of 
stimulus type, Helmert contrasts first compared standards with 
targets and distracters, and then compared targets with distract-
ers. For P3 ANOVAs examining effects of midline electrode site, 
Helmert contrasts compared electrodes in a posterior-frontal 
progression (Pz, PCz, Cz, FCz).
resUlTs
Oddball Task Performance
Behavioral data from the oddball task are presented in Table 2. 
Planned contrasts revealed a main effect of stimulus type 
[F(1,24) = 9.5, p < 0.01, η2 = 0.28], such that error responses to 
distracters (false alarms) and targets (misses) were more common 
than errors to standards. Distracter type significantly interacted 
with stimulus type [F(1,24) = 12.6, p < 0.01, η2 = 0.35], as false 
alarms to distracters were more common than target misses dur-
ing trial blocks presenting colorful distracters. There was a main 
effect of group, in which PD patients committed more errors over-
all than controls [F(1,24) = 20.5, p < 0.001, η2 = 0.46]. Group also 
interacted with distracter type [F(1,24) = 5.8, p < 0.05, η2 = 0.20], 
such that controls’ accuracy was greater than PD patients in the 
gray distracter block. Target RT data did not differ as a function 
of either group or distracter type (ps > 0.5).
event-related Potential Data
Within the gray distracter block, standard stimuli waveforms 
contained an average (±SD) of 163.7 ± 28.4 trials, while target 
waveforms contained 32.9 ± 8.1 trials and distracter waveforms 
contained 34.8 ± 6.8. Within the color distracter block, standard 
stimuli waveforms contained an average (±SD) of 173.5 ± 18.8 
trials, while target waveforms contained 34.4 ± 7.0 trials and dis-
tracter waveforms contained 36.2 ± 4.7. PD patients and controls 
did not differ in their number of trials that were acceptable for 
analysis.
P3 Amplitude and Latency
P3 activity had a broad distribution for healthy controls, while 
PD patients showed marked reductions in centrofrontal P3 
amplitudes for distracters and targets presented during the color 
distracter block. Peak P3 potentials for targets were seen in pari-
etal regions. Relative to controls, PD patients exhibited reduced 
centrofrontal P3 amplitude for distracters relative to targets and 
standards in the color distracter block [F(1,24) = 5.9, p < 0.05, 
η2 = 0.20]. This interaction resulted from attenuated distracter-
related centrofrontal P3 amplitude for PD patients relative to 
controls in the color distracter block, as shown in Figure 2.
Midline P3 latencies peaked between 350 and 500 ms across 
conditions. Over central sites, P3 latencies were shorter for 
distracters relative to other stimuli [F(1,24)  =  4.4, p  <  0.05, 
η2 = 0.15]. Overall P3 latencies were longer for PD patients than 
controls over central sites [F(1,24) = 9.2, p < 0.01, η2 = 0.28].
P3 Difference Waves and Clinical Symptoms in PD
Even though significant P3 group differences were observed 
for colorful distracter stimuli, standard stimuli did not 
demonstrate P3 effects of group (PD mean =  4.24 ±  2.65 μV; 
FigUre 2 | grand-averaged erPs from centrofrontal electrodes. Scalp 
maps illustrate peak P3 amplitudes evoked by distracters, which show a 
centrofrontal reduction in color distracter processing in PD patients. Target 
P3 amplitudes peaked in parietal electrodes (ERPs not shown). Note: voltage 
ranges for scalp maps were identical for each group (−5 to +7.5 μV).
FigUre 3 | centrofrontal difference waves, which show amplitude 
contrasts for distracter-standard conditions (dark and dotted lines) 
and standard stimuli taken from color and gray distracter blocks 
(gray line). ERPs to standard stimuli did not differ as a function of distracter 
color (flat line), so effects seen in distracter-standard difference waves were 
attributable to the distracters. Scalp maps illustrate distracter-standard P3 
difference waves (i.e., P3a), revealing a centrofrontal reduction in color-related 
distracter processing in PD patients. Note: voltage ranges for scalp maps 
were identical for each group (−4 to +2 μV).
TaBle 3 | intercorrelations for centrofrontal distracter-related P3 
amplitude and emotional symptoms in PD patients.
Measure 1 2 3 4 5
1. Color P3 difference wave –
2. Apathy Scale −0.80*** –
3. BDI-II −0.64* 0.90*** –
4. STAI – trait Anxiety −0.79* 0.88*** 0.91*** –
5. STAI – state Anxiety −0.83*** 0.77** 0.80*** 0.83*** –
*p < 0.05.
**p < 0.01.
***p < 0.001.
TaBle 4 | intercorrelations for centrofrontal distracter-related P3 amplitude, 
executive function, and apathy in PD patients.
Measure 1 2 3 4 5
1. Color P3 difference wave –
2. Trails B −0.49t –
3. Stroop color-word 0.69* −0.62t –
4. Wisconsin perseverative 
responses
−0.73** 0.26 −0.67* –
5. Apathy Scale −0.80*** 0.69** −0.73** 0.56* –
tp < 0.10.
*p < 0.05.
**p < 0.01.
***p < 0.001.
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Control mean  =  4.47  ±  2.61  μV) or distracter block (Color 
mean = 4.33 ± 2.67 μV; Gray mean = 4.37 ± 2.50 μV). In order to 
better isolate P3 signals (i.e., P3a) associated with color distracter 
processing in PD patients, color distracter-standard difference 
waves were calculated. The resulting difference wave was then 
scored for mean amplitude during the time interval correspond-
ing to maximal P3 amplitude (380–420 ms). Distracter-standard 
difference waves are shown in Figure 3.
Color distracter-standard P3 amplitudes (from now on 
referred to as color P3) were found to correlate with all emotional 
symptom scales in PD patients, as shown in Table 3. Because of 
the high degree of intercorrelations between emotional measures, 
partial correlations were performed such that each emotional 
measure was correlated with color P3 amplitudes, while control-
ling for all other emotional measures. Of these partial correla-
tions, only apathy remained significantly correlated with color P3 
in PD patients (r = −0.65, p < 0.05).
Color P3 amplitudes were also found to correlate with several 
executive function measures in PD patients, as shown in Table 4. 
Apathy scores also correlated with these measures of executive 
function. Partial correlations revealed that WCST perseverative 
responses remained significantly correlated with color P3 ampli-
tudes, even after controlling for the other executive function 
measures and apathy scores (r = −0.81, p = 0.05). Furthermore, 
partial correlations between apathy scores and color P3 ampli-
tudes also remained significant, after controlling for the executive 
function measures (r = −0.84, p < 0.05). These significant partial 
correlation plots can be seen in Figure 4.
FigUre 4 | Partial correlation plots illustrating the unique relationships between color distracter-related P3 amplitude and apathy (left) and WcsT 
perseverative responses (right). The negative relationship between color P3 amplitude and apathy was significant, even after controlling for the effects of other 
emotional scales and executive function. The negative relationship between color P3 amplitude and WCST perseverative responses was significant, even after 
controlling for the effects of apathy and other executive function measures.
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Parkinson’s disease motor symptoms (e.g., disease dura-
tion, symptom severity) and patient age did not significantly 
correlate with color P3 amplitudes. Similarly, measures of 
oddball task performance (i.e., target RT, target, and dis-
tracter accuracy) did not correlate with color P3 amplitudes. 
Furthermore, gray distracter-standard P3 amplitudes were not 
correlated with any of the clinical measures in PD patients. 
Additionally, none of these variables correlated with color P3 
amplitudes in controls.
DiscUssiOn
In this study, we examined ERP reflections of distracter novelty 
in order to test the hypothesis that heightened levels of apathy 
would be associated with decreased visual novelty processing 
in a heterogeneous sample of PD patients. In support of our 
hypothesis, this study revealed three major findings. First, PD 
patients exhibited reduced distracter-related ERPs over cen-
trofrontal electrode sites, indicating disruptions in attentional 
orienting toward novelty. Second, apathy symptoms were strong 
predictors of these P3 potentials, such that elevations in apathy 
corresponded with reductions in P3 amplitude across all PD 
patients. Although other emotional symptoms also correlated 
with P3 amplitude, these relationships disappeared when control-
ling for apathy. Third, executive functioning in PD independently 
correlated with distracter-related P3 potentials; however, apathy 
remained a significant predictor even when accounting for execu-
tive function.
novelty and P3 Potentials
Our finding of reduced centrofrontal P3 amplitudes in PD patients 
is consistent with earlier research (25), supporting the notion that 
PD patients exhibit dysfunction in novelty processing that can 
be observed as a centrofrontal electrophysiological deficit. The 
fact that these effects were sensitive to distracter content (i.e., 
lowest P3 amplitudes for unique color patterns) suggests that 
PD patients have disproportionate difficulty processing visual 
information that is both distracting and highly novel. Although 
it was predicted that distracter-related P3 activity would correlate 
with apathy symptoms in PD patients, it was not expected that 
emotional symptoms as a whole would be so highly associated 
with color P3 potentials. While these findings may suggest that 
the novelty processing in PD is associated with a broadly defined 
state of negative affect, the core emotional symptom driving this 
effect was shown to be apathy.
Similar to other previous findings (19), several executive func-
tioning measures were also correlated with reductions in color 
P3 amplitudes in PD. This allowed us to examine the degree to 
which apathy and executive functioning could be distinguished 
in their contributions to P3 amplitude. When controlling for the 
overall variance among these measures, apathy and perseverative 
errors on the WCST demonstrated unique relationships with 
color P3 amplitude, revealing that both emotional and executive 
symptoms are closely related to novelty processing deficits in 
PD. Although previous studies have found relationships between 
WCST performance and distracter-related P3 amplitudes in PD 
(19, 25), our findings are the first to show that apathy and execu-
tive function are independently linked to novelty processing in 
this population.
implications of novelty Processing 
Deficits in PD
The strong association between apathy symptoms and novelty 
processing suggests that the neural systems underlying motiva-
tion and attention are intricately linked in PD. This connection 
is consistent with our current understanding of apathy. Marin 
(16) regarded apathy as a primary deficit in motivation and 
goal-directed behavior. Although novelty processing is often 
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conceptualized as an automatic reflex that orients attention 
toward unexpected events, novelty processing can be vulnerable 
to top-down modulation.
Using a three-stimulus oddball task similar to the one involved 
in this project, Chong et al. (41) included a condition in which 
participants were instructed to visually explore the novel stimuli 
as task-relevant “invitations” for further processing, rather than 
ignoring them as task-irrelevant distracters. This condition led to 
enhanced novelty processing, as reflected in larger P3 amplitudes, 
and provided evidence that changes in context – both experimen-
tally and personally derived – can have dramatic changes on how 
novel information is processed. One can speculate that apathy 
symptoms in the PD patients had the opposite effect of Chong 
et al.’s invitation to visually explore the novel distracters. In the 
current study, PD patients did not selectively ignore these stimuli, 
as false alarm rates were not significantly different between color 
and gray distracters. However, it appears that their attentional 
orienting mechanisms failed to fully “explore” these novel events 
in a manner that is consistent with their self-reported symptoms 
of apathy.
limitations
Several limitations of the present study need to be acknowledged. 
The PD sample was variable with regard to disease duration, yet 
most of the PD patients were in H-Y stages 2–3. Patients were 
tested on dopaminergic medications, so specific effects of medi-
cation could not be addressed in the current study. While PD 
patients were more depressed and anxious than controls, they 
did not endorse greater apathy symptoms as a whole. As a result, 
only a small number of PD patients in this study were suffering 
from clinical levels of apathy. Nevertheless, the strong correla-
tions between apathy and P3 amplitudes seen across all patients 
demonstrate the utility of examining apathy in a continuous man-
ner. While apathy cut-off scores are meaningful for characterizing 
the clinical level of apathy severity in PD patients, our results 
show that levels of apathy need not be excessive in order to show 
strong associations with novelty processing. Other limitations are 
that the PD sample was well educated, predominantly male, and 
variable in age (43–77 years). As a result, these findings may not 
generalize to all PD patients. However, the variability observed 
in age, disease duration, and symptom severity did confound the 
results of this study, as these variables were not associated with 
emotional symptoms, cognitive symptoms, or distracter-related 
P3 potentials.
cOnclUsiOn
In summary, our findings support the hypothesis that apathy 
and executive functioning in PD are both strongly associated 
with deficits in novelty processing. PD patients showed reduced 
processing of novel distracters, as measured by the amplitude 
of centrofrontal distracter-related P3 components. Distracter-
related P3 amplitudes were strongly associated with apathy 
symptoms, even after controlling for the effects of depression, 
anxiety, and executive function. These findings help to clarify 
the psychophysiological implications of apathy, and may help 
facilitate a more biological understanding of this common 
symptom of PD. The combined effects of apathy, executive 
dysfunction, and novelty processing have far-reaching implica-
tions for goal-directed behavior in this population. Failure to 
orient attention appropriately may leave PD patients lost in a 
world of constantly changing attentional demands. These core 
deficits in attention may strip PD patients of the cognitive and 
motivational tools needed to flexibly respond to their environ-
ments. Further research is needed to better characterize the 
neural basis of these findings and determine how these deficits 
can be optimally managed to improve quality of life in this 
clinical population.
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